Yahoo Finance12d
Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
no FDA-approved drug therapies currently exist, leaving a significant unmet medical need. “The submission of our Investigator’s Brochure application marks a critical step forward in advancing ...
Business Insider12d
Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
Despite the high incidence of concussions, no FDA-approved drug therapies currently exist, leaving a significant unmet medical need. “The submission of our Investigator’s Brochure application marks a ...
Nasdaq12d
Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Australia for Mild Traumatic Brain Injury
no FDA-approved drug therapies currently exist, leaving a significant unmet medical need. “The submission of our Investigator’s Brochure application marks a critical step forward in advancing ...